Amendment · H.Amdt. 23· House of Representatives(119-HAMDT-23)
An amendment numbered 1 printed in Part A of House Report 119-130 to require all HHS regulations or guidance documentation to use language that is inclusive of all opioid overdose reversal drugs that have been approved by FDA, instead of referring to brand names.
Age: 36 years
Pennsylvania
- Introduced
- 6/4/2025
- Last activity
- 6/4/2025 — On agreeing to the Bresnahan amendment (A001) Agreed to by voice vote.
- Sponsored by
- Robert Bresnahan
- Cosponsors
- None
- Changes bill
- 119-HR-2483 — SUPPORT for Patients and Communities Reauthorization Act of 2025
- Introduced
- Passed House
- Adopted
What this amendment would do
This amendment's text has not been analysed yet.
- 6/4/2025
- House amendment agreed to: On agreeing to the Bresnahan amendment (A001) Agreed to by voice vote.
- House Amendment Offered
- Amendment (A001) offered by Mr. Bresnahan. (consideration: CR H2453; text: CR H2453)
- On agreeing to the Bresnahan amendment (A001) Agreed to by voice vote.
This bill has no cosponsors
No text available.